Although clinical presentation is usually sufficient for the initial diagnosis of AD, CSF biomarkers amyloid-beta 42 (Aβ42), phosphorylated tau (p-tau), and total tau are confirmatory tools [1]. The gene discussed is MAPT; the disease is Alzheimer disease.